Phase 3 Peripheral T Cell Lymphoma Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine68 enrolled1 locationNCT07414758
Recruiting
Phase 2Phase 3
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine40 enrolled1 locationNCT07389616
Recruiting
Phase 3
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Relapsed/Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc.120 enrolled1 locationNCT06776952
Recruiting
Phase 3
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Peripheral T Cell Lymphoma
Dizal Pharmaceuticals218 enrolled50 locationsNCT07234162
Recruiting
Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Peripheral T Cell Lymphoma
Acrotech Biopharma Inc.504 enrolled69 locationsNCT06072131